Psychiatr. praxi 2017; 18(2): 60-63 | DOI: 10.36290/psy.2017.011

Treatment of depressive disorder with cognitive dysfunction

prof. MUDr. Eva Češková, CSc.
1CEITEC-MU, Brno
2Psychiatrická klinika FN Brno
3KNP LF Ostravské univerzity, Ostrava
4Oddělení psychiatrie, FN Ostrava

Cognitive dysfunction frequently occurs in acute depression and can persist into remission. Cognitive impairments impacts on

patient functioning and negatively influence ability to perform adequately at work. As evidenced by the results of numerous

studies drugs with anticholinergic effect (e. g. tricyclic antidepressants) may adversly affect cognitive functions. The most frequently

prescribed antidepressants, selective serotonin reuptake inhibitors may improve cognitivy dysfunction in depression.

Agent also including a noradrenergic component such as selective serotonin and noradrenaline reuptak inhibitorts appears to

be more effective in respect to cognitive functions compared to SSRI treatment. Based on the available data, the new multimodal

antidepressant vortioxetine may have a specific pro-cognitive effects.

Keywords: cognitive dysfunction, depressive disorder, antidepressants, negative bias

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Treatment of depressive disorder with cognitive dysfunction. Psychiatr. praxi. 2017;18(2):60-63. doi: 10.36290/psy.2017.011.
Download citation

References

  1. Hammar A, Ardal G. Cognitive functioning in major depression - a summary. Front Hum Neurosci 2009; 3: 1-7. Go to original source... Go to PubMed...
  2. Gonda X, Pompili M, Serafini G, et al. The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry 2015; 14: 27. Go to original source... Go to PubMed...
  3. Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Brit J Clin Pharmacol 2005; 59: 143-151. Go to original source... Go to PubMed...
  4. Dal Pozzo C, Kerr JS, Balguranidis C, et al. The effects of acute doses of dothiepin (25, 50, and 75 mg) versus placebo on psychomotor performance and cognitive function. Hum Psychopharmacol 1997; 12: 337-345. Go to original source...
  5. Fairweather DB, Kerr JS, Harrison DA, et al. A duble blind comparison of the effects of fluoxetine and amitryptyline on cognitive function in elderly depressed patients. Hum Psychopharmacol 1993; 8: 41-47. Go to original source...
  6. Fairweather DB, Dal Pozzo C, Kerr JS, et al. Citalopram compared to dothiepine and placebo: effects on cognitive function and psychomotor performance. Hum Psychopharmacol 1997; 12: 119-126. Go to original source...
  7. Savaskan E, Muller SE, Bohringer A, et al. Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. Int J Neuropsychopharm 2008; 11: 381-388. Go to original source... Go to PubMed...
  8. Constant EL, Adam S, Gillain B, et al. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety 2005; 21: 78-89. Go to original source... Go to PubMed...
  9. Schrijvers D, Maas YJ, Pier MP, et al. Psychomotor changes in major depressive disorder during sertraline treatment. Neuropsychobiology 2009; 59: 34-42. Go to original source... Go to PubMed...
  10. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 2009; 43: 855-863. Go to original source... Go to PubMed...
  11. Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 2010; 177: 323-329. Go to original source... Go to PubMed...
  12. Borkowska A, Pietrzak I, Rybakowski J. Procognitive influence of moclobemide in vascular depression. Pharmacother Psychiatr Neurol 2005; 2: 167-173.
  13. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998; 59: 8-10.
  14. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003; 18: 9-14. Go to original source... Go to PubMed...
  15. Gualtieri CT, Johnson LG. Bupropion normalizes cognitive performance in patients with depression. MedGenMed 2007; 9: 22.
  16. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340: 666-675. Go to original source... Go to PubMed...
  17. Leiser SC, Pehrson AL, Dale E, et al. Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: A review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine. ACS Chem Neurosci 2015; 6: 970-986. Go to original source... Go to PubMed...
  18. Frampton JE. Vortioxetine: A review in cognitive dysfunction in depression. Drugs 2016; 76: 1675-1682. Go to original source... Go to PubMed...
  19. Gorenstein C, de Carvalho SC, Artes R, et al. Cognitive performance in depressed patients after chronic use of antidepressants. Psychopharmacol 2006; 185: 84. Go to original source... Go to PubMed...
  20. Douglas KM, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Aust N Z J Psychiatry 2009; 43: 1105-1117. Go to original source... Go to PubMed...
  21. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr 2013; 18: 139-149. Go to original source... Go to PubMed...
  22. Tsourtos G, Thompson JC, Stough C. Evidence of an early information processing speed deficit in unipolar major depression. Psychol Med 2002; 32: 259-265. Go to original source... Go to PubMed...
  23. Navrátilová, P, Přikrylová-Kučerová H, Ustohal L. Klinicky významná změna kognitivního výkonu při léčbě antidepresivy. In Psychiatrie, supl. 1, 2009. 1 s.
  24. Withall A, Harris LM, Cumming SR. The relationship between cognitive function and clinical and functional outcomes in major depressive disorder. Psychol Med 2009; 39: 393-402. Go to original source... Go to PubMed...
  25. Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychother Psychosom 2004; 73: 380-385. Go to original source... Go to PubMed...
  26. Hasselbalch BJ, Knorr U, Hasselbalch, SG, Gade A, Kessing LV. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology 2012; 26: 642-651. Go to original source... Go to PubMed...
  27. Ragguett R-M, Cha DS, Kakar R, Rosenblat JD, Lee Y, McIntyre RS. Assessing and measuring cognitive function in major depressive disorder. Evid Based Ment Health 2016; 19: 106-109. Go to original source... Go to PubMed...
  28. Biringer E, Arvid R, Anders L. A review of modern antidepressants' effects on neurocognitive function. Curr Psychiatry Rev 2009; 5: 164-174. Go to original source...
  29. Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29: 639-658. Go to original source...
  30. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology 2003; 170: 225-234. Go to original source... Go to PubMed...
  31. Ott CV, Bjertrup AJ, Jensen JH, et al. Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools. J Affect Disord 2016; 190: 607-615. Go to original source... Go to PubMed...
  32. Roiser JP, Elliott R, Sahakian BJ. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 2012; 37: 117-136. Go to original source... Go to PubMed...
  33. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Brit J Psychiatry. 2009; 195: 102-108. Go to original source... Go to PubMed...
  34. Dunn TW, Vittengl JR, Clark LA, et al. Change in psychosocial functioning and depressive symptoms during acute-phase cognitive therapy for depression. Psychol Med 2011; 25: 1-10.
  35. Bowie CR, Gupta M, Holshausen K. Cognitive remediation therapy for mood disorders: rationale, early evidence, and future directions. Can J Psychiatry 2013; 58: 319-325. Go to original source... Go to PubMed...
  36. Iacoviello BM, Wu G, Alvarez E, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety 2014; 31: 699-706. Go to original source... Go to PubMed...
  37. Klasik A, Krysta K, Krzystanek M. Impact of psychotherapy and antidepressive treatment on cognitive functions in patients treated for dpression. Psychiatr Danub 2012; 24: 130-134. Go to PubMed...
  38. MacQueen GM, Katherine A, Memedovich, BHSc (candidate) Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options. Psychiatry Clin Neurosci 2017; 71: 18-27. Go to original source...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.